Immune modulation by zoledronic acid in human myeloma: An advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells

Journal of Immunology

Volumn 187, Issue 4, 2011, Pages 1578-1590

  Castella, Barbara ^a   Riganti, Chiara ^b   Fiore, Francesca ^a,c   Pantaleoni, Francesca ^a   Canepari, Maria Elisa ^a   Peola, Silvia ^a   Foglietta, Myriam ^a,c   Palumbo, Antonio ^c   Bosia, Amalia ^b   Coscia, Marta ^a,c   Boccadoro, Mario ^c   Massaia, Massimo ^a,c  

^a Laboratorio di Ematologia Oncologica   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPENTENYL DIPHOSPHATE; MEVALONIC ACID; PROGRAMMED DEATH 1 LIGAND 2; SURVIVIN; ZOLEDRONIC ACID;

ARTICLE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD80; BONE DENSITY CONSERVATION AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL PROLIFERATION; DENDRITIC CELLS; DIPHOSPHONATES; GENE EXPRESSION REGULATION; HEMITERPENES; HUMANS; IMIDAZOLES; LYMPHOCYTE ACTIVATION; MEVALONIC ACID; MONOCYTES; MULTIPLE MYELOMA; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA;

EID: 80051944692     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002514     Document Type: Article

References (48)

1. Beetz, S., D. Wesch, L. Marischen, S. Welte, H. H. Oberg, and D. Kabelitz. 2008. Innate immune functions of human gammadelta T cells. Immunobiology 213: 173-182. (Pubitemid 351484782)
2. Tanaka, Y., C. T. Morita, Y. Tanaka, E. Nieves, M. B. Brenner, and B. R. Bloom. 1995. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375: 155-158.
3. Jomaa, H., J. Feurle, K. Lühs, V. Kunzmann, H. P. Tony, M. Herderich, and M. Wilhelm. 1999. Vgamma9/Vdelta2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol. Med. Microbiol. 25: 371-378. (Pubitemid 29397507)
4. Espinosa, E., C. Belmant, F. Pont, B. Luciani, R. Poupot, F. Romagné, H. Brailly, M. Bonneville, and J. J. Fournié. 2001. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J. Biol. Chem. 276: 18337-18344.
5. Bonneville, M., and E. Scotet. 2006. Human Vgamma9Vdelta2 T cells: Promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18: 539-546. (Pubitemid 44311448)
6. Gober, H. J., M. Kistowska, L. Angman, P. Jenö, L. Mori, and G. De Libero. 2003. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197: 163-168. (Pubitemid 36152311)
7. Roelofs, A. J., K. Thompson, S. Gordon, and M. J. Rogers. 2006. Molecular mechanisms of action of bisphosphonates: Current status. Clin. Cancer Res. 12: 6222s-6230s. (Pubitemid 44703794)
8. Mönkkönen, H., P. D. Ottewell, J. Kuokkanen, J. Mönkkönen, S. Auriola, and I. Holen. 2007. Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci. 81: 1066-1070. (Pubitemid 47418845)
9. Mariani, S., M. Muraro, F. Pantaleoni, F. Fiore, B. Nuschak, S. Peola, M. Foglietta, A. Palumbo, M. Coscia, B. Castella, et al. 2005. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19: 664-670. (Pubitemid 40521173)
10. Roelofs, A. J., M. Jauhiainen, H. Mönkkönen, M. J. Rogers, J. Mönkkönen, and K. Thompson. 2009. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 144: 245-250.
11. Fiore, F., B. Castella, B. Nuschak, R. Bertieri, S. Mariani, B. Bruno, F. Pantaleoni, M. Foglietta, M. Boccadoro, and M. Massaia. 2007. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 110: 921-927. (Pubitemid 47267430)
12. Conti, L., R. Casetti, M. Cardone, B. Varano, A. Martino, F. Belardelli, F. Poccia, and S. Gessani. 2005. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: Role of CD86 and inflammatory cytokines. J. Immunol. 174: 252-260. (Pubitemid 40007411)
13. Devilder, M.-C., S. Maillet, I. Bouyge-Moreau, E. Donnadieu, M. Bonneville, and E. Scotet. 2006. Potentiation of antigen-stimulated V γ 9V δ 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J. Immunol. 176: 1386-1393. (Pubitemid 43134280)
14. Takahara, M., M. Miyai, M. Tomiyama, M. Mutou, A. J. Nicol, and M. Nieda. 2008. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. J. Leukoc. Biol. 83: 742-754. (Pubitemid 351966884)
15. Kunzmann, V., E. Bauer, J. Feurle, F. Weissinger, H. P. Tony, and M. Wilhelm. 2000. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392. (Pubitemid 30463353)
16. Wilhelm, M., V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger, T. Ruediger, and H. P. Tony. 2003. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102: 200-206. (Pubitemid 36759655)
17. Kunzmann, V., B. Kimmel, T. Herrmann, H. Einsele, and M. Wilhelm. 2009. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4 + CD25+ FoxP3+ regulatory T cells. Immunology 126: 256-267.
18. Brown, R. D., B. Pope, A. Murray, W. Esdale, D. M. Sze, J. Gibson, P. J. Ho, D. Hart, and D. Joshua. 2001. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98: 2992-2998.
19. Ratta, M., F. Fagnoni, A. Curti, R. Vescovini, P. Sansoni, B. Oliviero, M. Fogli, E. Ferri, G. R. Della Cuna, S. Tura, et al. 2002. Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 100: 230-237. (Pubitemid 35177452)
20. Cabillic, F., O. Toutirais, V. Lavoué, C. T. De La Pintière, P. Daniel, N. Rioux-Leclerc, B. Turlin, H. Mönkkönen, J. Mönkkönen, K. Boudjema, et al. 2010. Aminobisphosphonate- pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol. Immunother. 59: 1611-1619.
21. Banerjee, D. K., M. V. Dhodapkar, E. Matayeva, R. M. Steinman, and K. M. Dhodapkar. 2006. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108: 2655-2661.
22. Fiore, F., B. Nuschak, S. Peola, S. Mariani, M. Muraro, M. Foglietta, M. Coscia, B. Bruno, M. Boccadoro, and M. Massaia. 2005. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur. J. Immunol. 35: 1155-1163. (Pubitemid 40542222)
23. Grube, M., S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler. 2007. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin. Cancer Res. 13: 1053-1060. (Pubitemid 46340385)
24. Dauer, M., B. Obermaier, J. Herten, C. Haerle, K. Pohl, S. Rothenfusser, M. Schnurr, S. Endres, and A. Eigler. 2003. Mature dendritic cells derived from human monocytes within 48 hours: A novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170: 4069-4076. (Pubitemid 36428169)
25. Mariani, S., S. Y. Hwang, M. Foglietta, L. Bonello, C. Vitale, M. Coscia, F. Fiore, B. Bruno, and M. Massaia. 2009. Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. Exp. Hematol. 37: 728-738.
26. Seifert, S. C., and J. J. Lucas. 1988. Incorporation of mevalonate into dolichol and other isoprenoids during estrogen-induced chick oviduct differentiation. Biochim. Biophys. Acta 962: 16-24.
27. Benford, H. L., J. C. Frith, S. Auriola, J. Mönkkönen, and M. J. Rogers. 1999. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 56: 131-140. (Pubitemid 29309821)
28. Kuniyasu, Y., T. Takahashi, M. Itoh, J. Shimizu, G. Toda, and S. Sakaguchi. 2000. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 12: 1145-1155. (Pubitemid 30618021)
29. Buhaescu, I., and H. Izzedine. 2007. Mevalonate pathway: A review of clinical and therapeutical implications. Clin. Biochem. 40: 575-584. (Pubitemid 46829082)
30. Thompson, K., and M. J. Rogers. 2004. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 19: 278-288. (Pubitemid 38116742)
31. Mahan, C. S., J. J. Thomas, W. H. Boom, and R. E. Rojas. 2009. CD4+ CD25 (high) Foxp3+ regulatory T cells downregulate human Vdelta2+ T-lymphocyte function triggered by anti-CD3 or phosphoantigen. Immunology 127: 398-407.
32. Wan, Y. Y., and R. A. Flavell. 2006. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol. Rev. 212: 114-130. (Pubitemid 44116704)
33. Klebanoff, C. A., L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A. R. Cardones, S. E. Finkelstein, D. C. Palmer, P. A. Antony, S. T. Hwang, S. A. Rosenberg, et al. 2005. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102: 9571-9576. (Pubitemid 40981722)
34. Gattinoni, L., C. A. Klebanoff, D. C. Palmer, C. Wrzesinski, K. Kerstann, Z. Yu, S. E. Finkelstein, M. R. Theoret, S. A. Rosenberg, and N. P. Restifo. 2005. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115: 1616-1626. (Pubitemid 40814670)
35. Dieli, F., F. Poccia, M. Lipp, G. Sireci, N. Caccamo, C. Di Sano, and A. Salerno. 2003. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med. 198: 391-397. (Pubitemid 36980610)
36. Parekh, V. V., S. Lalani, S. Kim, R. Halder, M. Azuma, H. Yagita, V. Kumar, L.Wu, and L. V. Kaer. 2009. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J. Immunol. 182: 2816-2826.
37. Blank, C., and A. Mackensen. 2007. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 56: 739-745. (Pubitemid 46348742)
38. Romagnoli, M., V. Trichet, C. David, M. Clément, P. Moreau, R. Bataille, and S. Barillé-Nion. 2007. Significant impact of survivin on myeloma cell growth. Leukemia 21: 1070-1078. (Pubitemid 46672084)
39. Andersen, M. H., L. O. Pedersen, J. C. Becker, and P. T. Straten. 2001. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61: 869-872. (Pubitemid 32175146)
40. Wobser, M., P. Keikavoussi, V. Kunzmann, M. Weininger, M. H. Andersen, and J. C. Becker. 2006. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 55: 1294-1298. (Pubitemid 43992055)
41. Andersen, M. H., I. M. Svane, J. C. Becker, and P. T. Straten. 2007. The universal character of the tumor-associated antigen survivin. Clin. Cancer Res. 13: 5991-5994. (Pubitemid 350075053)
42. Dauer, M., K. Schad, J. Herten, J. Junkmann, C. Bauer, R. Kiefl, S. Endres, and A. Eigler. 2005. FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J. Immunol. Methods 302: 145-155. (Pubitemid 41111881)
43. Jarnjak-Jankovic, S., H. Hammerstad, S. Saebøe-Larssen, G. Kvalheim, and G. Gaudernack. 2007. A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 7: 119-125.
44. Gao, Y., W. Yang, M. Pan, E. Scully, M. Girardi, L. H. Augenlicht, J. Craft, and Z. Yin. 2003. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198: 433-442. (Pubitemid 36976054)
45. Gong, G., L. Shao, Y. Wang, C. Y. Chen, D. Huang, S. Yao, X. Zhan, H. Sicard, R. Wang, and Z. W. Chen. 2009. Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. Blood 113: 837-845.
46. Joshua, D. E., R. D. Brown, P. J. Ho, and J. Gibson. 2008. Regulatory T cells and multiple myeloma. Clin. Lymphoma Myeloma 8: 283-286.
47. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704. (Pubitemid 351600389)
48. Stresing, V., P. G. Fournier, A. Bellahcène, I. Benzaïd, H. Mönkkönen, M. Colombel, F. H. Ebetino, V. Castronovo, and P. Clézardin. 2011. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 48: 259-266.